Topics

After Suspending Generics Spin-Off, Mallinckrodt Eyes Potential FDA Approval of Liver Disease Drug

20:00 EDT 14 Aug 2019 | BioSpace

Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1.

Original Article: After Suspending Generics Spin-Off, Mallinckrodt Eyes Potential FDA Approval of Liver Disease Drug

NEXT ARTICLE

More From BioPortfolio on "After Suspending Generics Spin-Off, Mallinckrodt Eyes Potential FDA Approval of Liver Disease Drug"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...